With all the attention the top-performing health care sector, and biopharmaceutical stocks in particular, are receiving, which biotech stocks are worth a look ahead of their first-quarter earnings reports? Analysts at Goldman Sachs have identified four that they are bullish on, and today’s article notes that “While their shares only suited for aggressive growth accounts with a high-risk profile, none of these companies is a proverbial one-trick pony. In addition, they all are potential takeover candidates.” For more, CLICK HERE.
While analysts at Goldman Sachs believe that the S&P 500 will rise to 3,000 by the end of the year, they also caution that, despite the market having rallied in recent days, more pain lies ahead in the coming weeks and that the market has not hit its coronavirus-induced bottom yet. When can market participants feel confident that the market has indeed hit bottom? The analysts outline three criteria that they believe must be met. CLICK HERE.